Elevai Labs, Inc. is a public company focused on advancing health technology through innovative artificial intelligence solutions. The company specializes in developing AI-driven platforms that enhance medical diagnostics, treatment planning, and patient care. By leveraging machine learning algorithms and data analysis, Elevai Labs aims to improve the accuracy and efficiency of healthcare delivery, ultimately transforming the way medical professionals make decisions and interact with patients. Their commitment to research and development positions them at the forefront of a rapidly evolving sector, addressing critical challenges in healthcare with cutting-edge technology. Read More
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
NEWPORT BEACH, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced the completion of Phase II of the AI Development Program (“Phase II”) with strategic partner Yuva Biosciences, Inc. (“YuvaBio”). As part of the Phase II objective, YuvaBio delivered to Northstrive a shortlist of small molecule candidates YuvaBio believes has the potential to promote mitochondrial health to combat obesity and cardiac diseases.
NEWPORT BEACH, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”) today announced that it will effect a 1-for-3.5 reverse stock split (the “Split”) of its issued and outstanding and authorized common stock, par value $0.0001 per share (“Common Stock”). The marketplace effective date of the Split will be September 2, 2025 at 9:30 am EST.
Stay up-to-date with the latest market trends one hour before the close of the markets on Friday. Explore the top gainers and losers during today's session in our detailed report.
NEWPORT BEACH, Calif., Aug. 22, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company” or “PMGC”) (Nasdaq: ELAB) a diversified holding company today announced it has entered into a warrant inducement agreement with existing institutional investors for the exercise of certain outstanding warrants that the Company issued on January 27, 2025. Pursuant to the warrant inducement agreement, the investors have agreed to exercise the outstanding warrants to purchase an aggregate of 827,900 shares of the Company's common stock at an amended exercise price of $2.015. The gross proceeds from the exercise of the warrants are expected to be approximately $1.67 million, prior to deducting placement agent fees and estimated offering expenses.
